ALHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alignment Healthcare Inc (ALHC) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company's revenue growth is impressive, the negative net income, declining EPS, insider and hedge fund selling, and lack of strong technical or proprietary trading signals suggest caution. The stock may be better suited for monitoring rather than immediate investment.
The technical indicators show mixed signals. The MACD is slightly positive but contracting, RSI is neutral at 29.376, and moving averages are converging. The stock is trading near its support level (S2: 16.542) after a significant drop of -3.81% in the regular market. The stock's short-term trend indicates a high probability of further decline (-2.37% next day, -3.15% next week).
Analysts have raised price targets significantly, with targets ranging from $25 to $30, indicating long-term growth potential.
Revenue growth is strong, with a 44.43% YoY increase in Q4 2025 and projected 2026 revenue of $5.1-$5.2 billion.
Insiders and hedge funds are selling heavily, with insider selling up 137.77% and hedge fund selling up 1606.19%.
Net income and EPS have declined significantly YoY (-64.60% and -68.75%, respectively).
CEO recently sold a significant number of shares.
The stock's short-term trend indicates further potential downside.
In Q4 2025, revenue increased by 44.43% YoY to $1.0128 billion, showing strong growth. However, net income dropped by 64.60% YoY to -$11.006 million, and EPS fell by 68.75% YoY to -0.05. Gross margin improved slightly to 11.4%, up 0.44% YoY. The company is experiencing strong top-line growth but struggling with profitability.
Analysts are bullish on the stock, with multiple firms raising price targets recently. JPMorgan, Baird, KeyBanc, TD Cowen, and Piper Sandler have all increased their targets, with the highest being $30. Analysts highlight strong AEP sales, retention, and growth potential in Medicare Advantage.
